Merit Medical Systems/$MMSI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Merit Medical Systems
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
- Ticker
- $MMSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,500
- Headquarters
- South Jordan, United States
- Website
- www.merit.com
MMSI Metrics
BasicAdvanced
$5.3B
33.10
$2.67
0.55
-
Price and volume
Market cap
$5.3B
Beta
0.55
52-week high
$94.85
52-week low
$59.74
Average daily volume
746K
Financial strength
Current ratio
4.522
Quick ratio
2.896
Long term debt to equity
0.465
Total debt to equity
0.471
Interest coverage (TTM)
6.92%
Profitability
EBITDA (TTM)
348.756
Gross margin (TTM)
48.98%
Net profit margin (TTM)
9.94%
Operating margin (TTM)
13.89%
Effective tax rate (TTM)
24.37%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
5.04%
Return on equity (TTM)
9.78%
Valuation
Price to earnings (TTM)
33.103
Price to revenue (TTM)
3.271
Price to book
3.04
Price to tangible book (TTM)
8.59
Price to free cash flow (TTM)
26.277
Free cash flow yield (TTM)
3.81%
Free cash flow per share (TTM)
3.365
Growth
Revenue change (TTM)
9.06%
Earnings per share change (TTM)
36.89%
3-year revenue growth (CAGR)
9.52%
10-year revenue growth (CAGR)
10.75%
3-year earnings per share growth (CAGR)
15.86%
10-year earnings per share growth (CAGR)
20.33%
What the Analysts think about MMSI
Analyst ratings (Buy, Hold, Sell) for Merit Medical Systems stock.
Analyst projections of the future price of Merit Medical Systems stock.
Bulls say / Bears say
Third-quarter organic constant-currency revenue rose 9%, with growth across both product groups, and Merit raised its full-year 2026 revenue and earnings guidance. That points to solid demand and improving near-term expectations. (Merit Medical Systems)
Merit expanded its non-GAAP operating margin to 21.3% from 19.7%, while non-GAAP EPS rose 22% year on year. The improvement suggests it is converting sales growth into stronger earnings despite cost pressures. (Merit Medical Systems)
Therapeutic products grew 11% organically in the third quarter, including 33% constant-currency growth in endoscopy and 16% in oncology. Merit is also adding temporary pacing systems designed for TAVR procedures through its Solo Pace acquisition, extending its cardiac therapies range. (The Motley Fool, GlobeNewswire)
Non-GAAP gross margin fell 80 basis points to 52.8% in the third quarter, as manufacturing variances, raw-material costs and freight weighed on results. Management also continued to estimate a roughly $16 million tariff impact for 2026, leaving profitability exposed to costs it cannot fully control. (The Motley Fool)
Merit cut its second-half China revenue outlook by about $4 million, citing volume-based purchasing and anti-corruption pressures. Those policies and the push towards locally made, lower-priced products could keep weighing on international sales. (The Motley Fool)
Management described strong competition for WRAPSODY in the US, calling the commercial environment a battle. Merit still expects only about $7 million of US WRAPSODY CIE revenue for 2026, so adoption may take time to become a meaningful growth driver. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
MMSI Financial Performance
Revenues and expenses
MMSI Earnings Performance
Company profitability
Upcoming events
No upcoming events
MMSI News
AllArticlesVideos
Funds containing MMSI
AllUSDEURGBP
Fund name | Fund size | $MMSI weighting |
|---|---|---|
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.30% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.30% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.18% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.18% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.